Literature DB >> 3535999

Cholinergic mechanisms in depression.

S C Dilsaver.   

Abstract

Evidence supporting a cholinergic hypothesis of depression is presented. First, cholinergic overdrive produces behavioral, neuroendocrine, and polysomnographic features of melancholia, and melancholics exhibit state-independent supersensitivity to cholinergic overdrive. Drugs inducing up-regulation and supersensitivity of cholinergic systems produce behavioral, polysomnographic, and neuroendocrine effects of melancholia when withdrawn. These observations also implicate cholinergic system supersensitivity as a factor in the pathophysiology of certain affective disorders. Cholinergic and monoaminergic mechanisms reciprocally regulate drive-reduction, and substances of abuse either activate monoaminergic networks or antagonize cholinergic systems. These points are consistent with the hypothesis that dynamic interaction between cholinergic and monoaminergic systems is involved in the regulation of mood and affect. Finally, antimuscarinic agents have antidepressant effects. Thus, the hypothesis that supersensitivity of cholinergic systems is involved in the pathophysiology of affective disorders is supported by several lines of evidence. This evidence is reviewed; directions for future research and promising methods of investigation are discussed.

Entities:  

Mesh:

Year:  1986        PMID: 3535999     DOI: 10.1016/0165-0173(86)90016-0

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  26 in total

Review 1.  Molecular studies of the neuronal nicotinic acetylcholine receptor family.

Authors:  J Lindstrom; R Schoepfer; P Whiting
Journal:  Mol Neurobiol       Date:  1987       Impact factor: 5.590

2.  Acetylcholine excites neocortical pyramidal neurons via nicotinic receptors.

Authors:  Tristan Hedrick; Jack Waters
Journal:  J Neurophysiol       Date:  2015-01-14       Impact factor: 2.714

3.  Effects of neonatal clomipramine on cholinergic receptor sensitivity and passive avoidance behavior in adult rats.

Authors:  J Prathiba; K B Kumar; K S Karanth
Journal:  J Neural Transm Gen Sect       Date:  1995

4.  Antidepressant-like effects of guanfacine and sex-specific differences in effects on c-fos immunoreactivity and paired-pulse ratio in male and female mice.

Authors:  Yann S Mineur; Matthew P Bentham; Wen-Liang Zhou; Margreet E Plantenga; Sherry A McKee; Marina R Picciotto
Journal:  Psychopharmacology (Berl)       Date:  2015-07-07       Impact factor: 4.530

5.  Association of m1 and m2 muscarinic receptor proteins with asymmetric synapses in the primate cerebral cortex: morphological evidence for cholinergic modulation of excitatory neurotransmission.

Authors:  L Mrzljak; A I Levey; P S Goldman-Rakic
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

6.  Cholinergic neurotransmission seems not to be involved in depression but possibly in personality.

Authors:  J Fritze; M Lanczik; E Sofic; M Struck; P Riederer
Journal:  J Psychiatry Neurosci       Date:  1995-01       Impact factor: 6.186

7.  Appearance of antidepressant-like effect by sildenafil in rats after central muscarinic receptor blockade: evidence from behavioural and neuro-receptor studies.

Authors:  C B Brink; J D Clapton; B E Eagar; B H Harvey
Journal:  J Neural Transm (Vienna)       Date:  2007-09-07       Impact factor: 3.575

8.  Physiological properties of cholinergic and non-cholinergic magnocellular neurons in acute slices from adult mouse nucleus basalis.

Authors:  Tristan Hedrick; Jack Waters
Journal:  PLoS One       Date:  2010-06-10       Impact factor: 3.240

Review 9.  Withdrawal phenomena associated with antidepressant and antipsychotic agents.

Authors:  S C Dilsaver
Journal:  Drug Saf       Date:  1994-02       Impact factor: 5.606

10.  Neurochemistry of the nucleus accumbens and its relevance to depression and antidepressant action in rodents.

Authors:  Yukihiko Shirayama; Shigeyuki Chaki
Journal:  Curr Neuropharmacol       Date:  2006-10       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.